Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 24, 2021
First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1Martin Reck, Tudor-Eliade Ciuleanu, Jong-Seok Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 12, 2022
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227Julie R Brahmer, Jong-Seok Lee, Tudor-Eliade Ciuleanu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 15, 2019
Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER<sup>+</sup> Invasive Breast Cancer (STAKT)John F R Robertson, Robert E Coleman, Kwok-Leung Cheung, et al.
Journal for Immunotherapy of Cancer|February 1, 2023
First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817Neal E Ready, Clarisse Audigier-Valette, Jonathan W Goldman, et al.
JTO Clinical and Research Reports|January 13, 2025
First-Line Chemo-Immunotherapy in SCLC: Outcomes of a Binational Real-World StudyLaura Moliner, Núria Zellweger, Sabine Schmid, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2019
Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic RecurrenceRaoul Charles Coombes, Karen Page, Raheleh Salari, et al.
Ecancermedicalscience|February 26, 2016
An Association of Cancer Physicians' strategy for improving services and outcomes for cancer patientsRichard Baird, Ian Banks, David Cameron, et al.
Pageof 6